Trastuzumab (HLX02) plus Pertuzumab as Dualtarget Neoadjuvant Therapy for HER2-positive Breast Cancer: A Real-World Study

被引：0
|
作者：
Liu, Yin
Zuo, Wen-Jia
Wang, Ruo-Xi
Wang, Zhong-Hua
Shao, Zhi-Ming
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
基金：
上海市自然科学基金;
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-11-20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-20
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-world first line use of trastuzumab biosimilar (HLX02), pertuzumab and chemotherapy for Chinese patients with HER2-positive metastatic breast cancer
    Zhang, Ruyan
    Song, Guohong
    Liu, Xiaoran
    Li, Hui-Ping
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [2] Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study
    Zhang, Ruyan
    Liu, Xiaoran
    Song, Guohong
    Zhang, Yan
    Li, Huiping
    [J]. CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 795 - 801
  • [3] Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer
    Ma, Xiangmin
    Zhang, Xiangmei
    Zhou, Xinping
    Ren, Xiaofei
    Ma, Xindi
    Zhang, Weifang
    Yang, Ruiling
    Song, Tao
    Liu, Yunjiang
    [J]. MEDICINE, 2022, 101 (40) : E30892
  • [4] A multicenter real-world study comparing the clinical equivalence of trastuzumab biosimilar HLX02 and reference trastuzumab in the treatment of HER-2-positive breast cancer
    Deng, Weishang
    Hu, Jia
    Yang, Sensen
    Xie, Zeyu
    Li, Mengting
    Li, Jinjian
    Zhuang, Wenbin
    Chen, Jisheng
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (07): : 3113 - 3122
  • [5] Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
    Hall, Benjamin James
    Bhojwani, Ajay Ashok
    Wong, Helen
    Law, Andrea
    Flint, Helen
    Ahmed, Eliyaz
    Innes, Helen
    Cliff, Joanne
    Malik, Zaf
    O'Hagan, Julie Elizabeth
    Hall, Allison
    Sripadam, Rajaram
    Tolan, Shaun
    Ali, Zulfiqar
    Hart, Clare
    Errington, Douglas
    Alam, Farida
    Giuliani, Rosa
    Mehta, Shaveta
    Khanduri, Sheena
    Thorp, Nicky
    Jackson, Richard
    Cicconi, Silvia
    Palmieri, Carlo
    [J]. BREAST JOURNAL, 2022, 2022
  • [6] Neoadjuvant pyrotinib plus trastuzumab, and chemoterapy in patients with HER2-positive early breast cancer: a real-world study
    Zhou, Jun
    Wang, Rui
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [7] The efficacy and safety of trastuzumab biosimilar HLX02 compared with reference trastuzumab plus pertuzumab in combination with chemotherapy as the first-line treatment for HER2 positive metastatic breast cancer: A real-world study in China.
    Yan, Ying
    Li, Huiping
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer
    Li, Ning
    Qiu, Meng
    Zhang, Yanqiao
    Yang, Mudan
    Lu, Linzhi
    Li, Wei
    Ma, Yuntao
    Hou, Xiaoming
    Sun, Guoping
    Cai, Mingquan
    Wang, Jingran
    Lu, Jianwei
    Zhong, Diansheng
    Huo, Zhibin
    Zhang, Jingdong
    Yin, Xianli
    Deng, Jun
    Liu, Zimin
    Pan, Hongming
    Chen, Ye
    Yang, Futang
    Yu, Haoyu
    Li, Jing
    Wang, Qingyu
    Zhu, Jun
    Li, Jin
    [J]. MED, 2024, 5 (10):
  • [9] Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)
    Gonzalez-Santiago, Santiago
    Saura, Cristina
    Ciruelos, Eva
    Luis Alonso, Jose
    de la Morena, Pilar
    Santisteban Eslava, Marta
    Gallegos Sancho, Maria Isabel
    de Luna, Alicia
    Dalmau, Elsa
    Servitja, Sonia
    Ruiz Borrego, Manuel
    Ignacio Chacon, Jose
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (02) : 469 - 479
  • [10] Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)
    Santiago González-Santiago
    Cristina Saura
    Eva Ciruelos
    José Luis Alonso
    Pilar de la Morena
    Marta Santisteban Eslava
    Maria Isabel Gallegos Sancho
    Alicia de Luna
    Elsa Dalmau
    Sonia Servitja
    Manuel Ruiz Borrego
    José Ignacio Chacón
    [J]. Breast Cancer Research and Treatment, 2020, 184 : 469 - 479
12345